letrozole / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 114 Diseases   361 Trials   361 Trials   7200 News 


«12...7677787980818283848586...100101»
  • ||||||||||  letrozole / Generic mfg.
    Trial completion date, Trial primary completion date:  Evaluation of IM Letrozole ISM (clinicaltrials.gov) -  Jan 22, 2019   
    P1,  N=120, Recruiting, 
    Trial completion date: Sep 2019 --> Jul 2020 | Trial primary completion date: Apr 2019 --> Jul 2020
  • ||||||||||  letrozole / Generic mfg.
    Trial completion, Enrollment change, Trial primary completion date:  Effects of Controlled Ovarian Hyperstimulation (COH) With Letrozole and Gonadotropin (clinicaltrials.gov) -  Dec 27, 2018   
    P=N/A,  N=9, Completed, 
    Phase classification: P1 --> P2 Recruiting --> Completed | N=12 --> 9 | Trial primary completion date: Jun 2015 --> Aug 2014
  • ||||||||||  letrozole / Generic mfg.
    Enrollment open:  Intrauterine Insemination With Letrozole Versus in Natural Cycle (clinicaltrials.gov) -  Dec 11, 2018   
    P=N/A,  N=100, Enrolling by invitation, 
    Trial primary completion date: Dec 2018 --> Dec 2019 Not yet recruiting --> Enrolling by invitation
  • ||||||||||  Piqray (alpelisib) / Novartis, Kisqali (ribociclib) / Novartis
    Enrollment closed, Trial primary completion date, Metastases:  CLEE011X2107: Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer (clinicaltrials.gov) -  Dec 5, 2018   
    P1,  N=256, Active, not recruiting, 
    We desperately need an effective adjuvant therapy for women with early stage uLMS. Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2019 --> Nov 2019
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Trial completion date, Trial primary completion date:  Palbociclib and FES PET (clinicaltrials.gov) -  Dec 5, 2018   
    P2,  N=15, Active, not recruiting, 
    Active, not recruiting --> Completed Trial completion date: Nov 2018 --> Nov 2019 | Trial primary completion date: Nov 2018 --> Nov 2019
  • ||||||||||  letrozole / Generic mfg.
    Enrollment open:  Letrozole in Post-Menopausal Patients with Operable Hormone-Sensitive Breast Cancer (clinicaltrials.gov) -  Nov 29, 2018   
    P1,  N=300, Recruiting, 
    Active, not recruiting --> Completed | N=45 --> 59 | Trial completion date: Oct 2019 --> Nov 2018 | Trial primary completion date: Oct 2019 --> Nov 2018 Not yet recruiting --> Recruiting
  • ||||||||||  Trial completion date, Trial primary completion date:  Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients (clinicaltrials.gov) -  Nov 23, 2018   
    P3,  N=107, Recruiting, 
    An alternative schedule of extended adjuvant endocrine therapy with letrozole, including intermittent administration, might be feasible and the results of the SOLE trial support the safety of temporary treatment breaks in selected patients who might require them. Trial completion date: Mar 2018 --> Jan 2019 | Trial primary completion date: Mar 2018 --> Dec 2018
  • ||||||||||  Soltamox (tamoxifen citrate) / Jazz
    Enrollment change, Trial withdrawal:  Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer (clinicaltrials.gov) -  Nov 21, 2018   
    P4,  N=0, Withdrawn, 
    Trial completion date: Oct 2018 --> Oct 2020 | Trial primary completion date: Oct 2018 --> Oct 2020 N=600 --> 0 | Not yet recruiting --> Withdrawn
  • ||||||||||  letrozole / Generic mfg., tamoxifen / Generic mfg.
    Trial completion date, Trial primary completion date:  TALES: Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial (clinicaltrials.gov) -  Nov 13, 2018   
    P3,  N=144, Recruiting, 
    Trial completion date: Jul 2019 --> Dec 2019 | Trial primary completion date: Jul 2019 --> Dec 2019 Trial completion date: Jan 2019 --> Dec 2019 | Trial primary completion date: Jan 2019 --> Dec 2019
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Tukysa (tucatinib) / Pfizer
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer (clinicaltrials.gov) -  Nov 7, 2018   
    P1/2,  N=40, Recruiting, 
    Recruiting --> Active, not recruiting | Initiation date: Nov 2016 --> Sep 2012 Trial completion date: Oct 2018 --> Oct 2020 | Trial primary completion date: Oct 2018 --> Oct 2019
  • ||||||||||  Piqray (alpelisib) / Novartis, Kisqali (ribociclib) / Novartis
    Trial completion date, Metastases:  CLEE011X2107: Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer (clinicaltrials.gov) -  Oct 31, 2018   
    P1,  N=270, Recruiting, 
    Trial completion date: Oct 2018 --> Oct 2020 | Trial primary completion date: Oct 2018 --> Oct 2019 Trial completion date: May 2019 --> Dec 2019
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion date, Trial primary completion date:  Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Subjects (clinicaltrials.gov) -  Oct 26, 2018   
    P1,  N=60, Recruiting, 
    ET + CDK4/6 or mTOR inhibitors are likely safe and effective in older patients with HR+, HER2- advanced breast cancer. Trial completion date: Sep 2018 --> Dec 2019 | Trial primary completion date: Sep 2018 --> Sep 2019
  • ||||||||||  letrozole / Generic mfg.
    Trial completion date, Trial primary completion date:  PLUM: Pilot of Letrozole for Uterine Myomas (clinicaltrials.gov) -  Oct 16, 2018   
    P4,  N=12, Completed, 
    Not yet recruiting --> Recruiting Trial completion date: Aug 2017 --> Dec 2017 | Trial primary completion date: Aug 2017 --> Dec 2017
  • ||||||||||  letrozole / Generic mfg.
    Trial completion date, Trial termination, Trial primary completion date, Surgery:  Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery (clinicaltrials.gov) -  Oct 15, 2018   
    P1,  N=213, Terminated, 
    Trial completion date: Aug 2017 --> Dec 2017 | Trial primary completion date: Aug 2017 --> Dec 2017 Trial completion date: Sep 2019 --> Sep 2018 | Active, not recruiting --> Terminated | Trial primary completion date: Mar 2019 --> Sep 2018; funding unavailable
  • ||||||||||  PF-06804103 / Pfizer
    Trial completion date, Trial primary completion date:  PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors (clinicaltrials.gov) -  Oct 15, 2018   
    P1,  N=95, Recruiting, 
    Trial completion date: Sep 2019 --> Sep 2018 | Active, not recruiting --> Terminated | Trial primary completion date: Mar 2019 --> Sep 2018; funding unavailable Trial completion date: Feb 2021 --> Jun 2021 | Trial primary completion date: Feb 2021 --> Jun 2021
  • ||||||||||  everolimus / Generic mfg.
    Trial completion date, Trial primary completion date:  Phase II Study of Everolimus Beyond Progression (clinicaltrials.gov) -  Oct 9, 2018   
    P2,  N=4, Active, not recruiting, 
    Trial completion date: Feb 2021 --> Jun 2021 | Trial primary completion date: Feb 2021 --> Jun 2021 Trial completion date: Sep 2019 --> Oct 2020 | Trial primary completion date: Sep 2018 --> Oct 2019
  • ||||||||||  Enrollment closed, PARP Biomarker:  PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial (clinicaltrials.gov) -  Oct 9, 2018   
    P2,  N=200, Active, not recruiting, 
    Trial completion date: Sep 2019 --> Oct 2020 | Trial primary completion date: Sep 2018 --> Oct 2019 Recruiting --> Active, not recruiting